title: Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma.
abstract: Spinal metastases from glioblastoma are extremely rare and may be misdiagnosed leading to a delay in investigation and treatment. Patient outcomes are poor with a high morbidity and mortality. Metastases are seen in the context of increasing survival due to improvements in glioblastoma therapies. We report a case of a patient developing a thoracic spinal cord metastasis while receiving anti-angiogenesis therapy with bevacizumab.
authors: Department of Oncology, Royal Melbourne Hospital, Grattan Street, Parkville, Victoria, 3050, Australia. annalomax@y7mail.com
authors: Anna J
authors: AJ
authors: Lomax
authors: Costas K
authors: CK
authors: Yannakou
authors: Mark A
authors: MA
authors: Rosenthal
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D006801:Humans; D008297:Male; D013120:Spinal Cord Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab